SCHEMBL1383101

SCHEMBL1383101

Nc1onc2cccc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 18/20 0.67
▸ FLT3 P36888 15/20 0.67
▸ KIT P10721 13/20 0.67
▸ PDGFRB P09619 7/20 0.61
▸ LCK P06239 2/20 0.57
▸ CSF1R P07333 2/20 0.57
▸ LYN P07948 2/20 0.57
▸ SRC P12931 2/20 0.57
▸ FLT1 P17948 2/20 0.57
▸ FLT4 P35916 2/20 0.57
▸ BLK P51451 2/20 0.57
▸ PLK4 O00444 1/20 0.57
▸ AURKA O14965 1/20 0.57
▸ JAK2 O60674 1/20 0.57
▸ ROCK2 O75116 1/20 0.57
▸ CHEK2 O96017 1/20 0.57
▸ NTRK1 P04629 1/20 0.57
▸ INSR P06213 1/20 0.57
▸ CDK1 P06493 1/20 0.57
▸ MET P08581 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1382612 0.90 KDR (0.68) KDRFLT3KITPDGFRBLCK
SCHEMBL4737316 0.90 KDR (0.68) KDRFLT3KITPDGFRBLCK
SCHEMBL1383493 0.89 KDR (0.72) KDRFLT3KITPDGFRBLCK
SCHEMBL4736063 0.89 KDR (0.70) KDRFLT3KITPDGFRBLCK
SCHEMBL1383479 0.89 KDR (0.70) KDRFLT3KITPDGFRBLCK
SCHEMBL5253141 0.89 KDR (0.70) KDRFLT3KITPDGFRBLCK
SCHEMBL4736275 0.88 KDR (0.71) KDRFLT3KITPDGFRBLCK
SCHEMBL4737823 0.87 KDR (0.70) KDRFLT3KITPDGFRBCSF1R
SCHEMBL4735263 0.87 KDR (0.70) KDRFLT3KITPDGFRBLCK
SCHEMBL1381023 0.87 KDR (0.70) KDRFLT3KITPDGFRBLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4810427-B2 — — 2011-11-09 — — JP claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 — — EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 — — WO claimed
EP-1638941-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-03-29 — — EP claimed
WO-2004113304-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-12-29 — — WO claimed
EP-1608352-A4 POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES TAIGEN BIOTECHNOLOGY CO LTD (TW) 2007-11-28 — — EP disclosed
EP-1608352-A1 POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES Taigen Biotechnology (TW) 2005-12-28 — — EP disclosed
WO-2004089360-A1 POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES TAIGEN BIOTECHNOLOGY (TW) 2004-10-21 — — WO disclosed
Send feedback